RAPT THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.04 USD | -2.42% |
|
-6.70% | -83.74% |
| May. 14 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
| May. 10 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 602.8 | 485 | 1,085 | 672 | 854.7 | 141 | - | - |
| Enterprise Value (EV) 1 | 527.6 | 373.5 | 895.6 | 422.9 | 854.7 | -10.98 | -74.68 | -113.1 |
| P/E ratio | -2.79 x | -9.02 x | -14.5 x | -7.67 x | -8.15 x | -1.44 x | -1.53 x | -1.08 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 96.2 x | 285 x | 440 x | - | - | - | 8.58 x |
| EV / Revenue | - | 74.1 x | 235 x | 277 x | - | - | - | -6.88 x |
| EV / EBITDA | -12.5 x | -7.17 x | -13.1 x | -4.99 x | -6.79 x | 0.09 x | 0.6 x | 0.95 x |
| EV / FCF | - | - | -14.5 x | -5.91 x | - | 0.09 x | 0.48 x | 0.54 x |
| FCF Yield | - | - | -6.9% | -16.9% | - | 1,097% | 208% | 185% |
| Price to Book | 8.24 x | 4.7 x | 5.82 x | 2.77 x | - | 1.18 x | 1.13 x | 0.97 x |
| Nbr of stocks (in thousands) | 21,831 | 24,555 | 29,546 | 33,940 | 34,396 | 34,903 | - | - |
| Reference price 2 | 27.61 | 19.75 | 36.73 | 19.80 | 24.85 | 4.040 | 4.040 | 4.040 |
| Announcement Date | 3/30/20 | 3/11/21 | 3/10/22 | 3/14/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 5.042 | 3.813 | 1.527 | - | - | - | 16.43 |
| EBITDA 1 | -42.3 | -52.09 | -68.21 | -84.75 | -125.8 | -124.7 | -125.1 | -119.6 |
| EBIT 1 | -43.63 | -53.21 | -69.21 | -85.8 | -127.1 | -116.8 | -139.1 | -195.7 |
| Operating Margin | - | -1,055.41% | -1,815.08% | -5,618.53% | - | - | - | -1,190.84% |
| Earnings before Tax (EBT) 1 | -42.34 | -51.9 | -69.2 | -83.84 | -116.8 | -109.1 | -130.2 | -278 |
| Net income 1 | -43 | -52.89 | -69.2 | -83.84 | -116.8 | -109.3 | -132.7 | -234.9 |
| Net margin | - | -1,049.03% | -1,814.95% | -5,490.37% | - | - | - | -1,429.21% |
| EPS 2 | -9.890 | -2.190 | -2.530 | -2.580 | -3.050 | -2.799 | -2.642 | -3.728 |
| Free Cash Flow 1 | - | - | -61.78 | -71.62 | - | -120.4 | -155 | -209 |
| FCF margin | - | - | -1,620.27% | -4,689.98% | - | - | - | -1,271.81% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/11/21 | 3/10/22 | 3/14/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.756 | 0.641 | 0.886 | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | -17.8 | -20.52 | -18.64 | -21.42 | -24.18 | -31.26 | -28.1 | -33.59 | -32.89 | - | - | - | - | - | - |
| EBIT 1 | -18.03 | -20.78 | -18.91 | -21.68 | -24.43 | -31.56 | -28.36 | -33.92 | -33.22 | -32.52 | -29.23 | -26.86 | -25.82 | -27.63 | -27.77 |
| Operating Margin | -2,385.45% | -3,241.34% | -2,134.2% | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -17.93 | -20.47 | -19.18 | -21.24 | -22.95 | -29.27 | -25.28 | -31.37 | -30.88 | -30.52 | -28.6 | -25.73 | -24.33 | -24.83 | -25.95 |
| Net income 1 | -17.93 | -20.47 | -19.18 | -21.24 | -22.95 | -29.27 | -25.28 | -31.37 | -30.88 | -30.52 | -28.84 | -25.74 | -24.2 | -24.83 | -25.95 |
| Net margin | -2,371.56% | -3,193.14% | -2,165.24% | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.6100 | -0.6900 | -0.6200 | -0.6300 | -0.6400 | -0.7600 | -0.6600 | -0.8200 | -0.8100 | -0.7900 | -0.7512 | -0.6257 | -0.5476 | -0.6486 | -0.6396 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/22 | 5/11/22 | 8/11/22 | 11/10/22 | 3/14/23 | 5/11/23 | 8/11/23 | 11/13/23 | 3/7/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 75.2 | 112 | 190 | 249 | - | 152 | 216 | 254 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -61.8 | -71.6 | - | -120 | -155 | -209 |
| ROE (net income / shareholders' equity) | -62.7% | -59.7% | -47.6% | -38.9% | - | -91.5% | -75.5% | -53.6% |
| ROA (Net income/ Total Assets) | - | - | -43.6% | -36.1% | - | -57.7% | -41.3% | - |
| Assets 1 | - | - | 158.8 | 232.4 | - | 189.4 | 321 | - |
| Book Value Per Share 2 | 3.350 | 4.210 | 6.310 | 7.160 | - | 3.410 | 3.580 | 4.150 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.89 | 0.4 | 0.76 | 0.85 | - | 2.16 | 2.23 | 3.52 |
| Capex / Sales | - | 7.89% | 19.8% | 55.34% | - | - | - | 21.41% |
| Announcement Date | 3/30/20 | 3/11/21 | 3/10/22 | 3/14/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
4.04
USD
Average target price
14.57
USD
Spread / Average Target
+260.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -83.74% | 141M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -14.15% | 21.84B | |
| -1.05% | 21.96B | |
| -5.29% | 19.21B | |
| -38.29% | 17.71B | |
| -4.16% | 18.08B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- RAPT Stock
- Financials RAPT Therapeutics, Inc.
